Randomized controlled trials have shown that renin-angiotensin II-aldosterone system inhibitors (RASIs), including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), may control blood pressure [1], reduce proteinuria [2, 3], and slow CKD progression to end-stage renal disease (ESRD) in the pediatric population [4]. The gene discussed is ACE; the disease is chronic kidney disease.